Crohn’s disease can be treated with medications that control inflammation and reduce the frequency of flareups for the intestinal disorder. These treatments include biologic drugs that target certain ...

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Sales of Skyrizi and Rinvoq ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

AbbVie ABBV announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s ...

In an increasingly crowded psoriasis market, a raft of next-gen biologics is looking to topple an older suite of drugs for sales supremacy. Dermatologists seem to be on board with that shift, a good ...

SKYRIZI ® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases, initially for Crohn’s ...

AbbVie’s Skyrizi topped the list as the biggest pharma drug ad spender in July for the second month in a row, but overall spending is falling off a cliff. Skyrizi, one of AbbVie's new Humira ...

April 23 (Reuters) - AbbVie Inc said on Tuesday that the U.S. Food and Drug Administration approved its Skyrizi drug as a treatment for plaque psoriasis at a time when its blockbuster psoriasis drug, ...

MONTREAL, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with ulcerative colitis (UC). Canada’s Drug Agency (CDA-AMC) has ...

FILE PHOTO: A trader works by the post that trades AbbVie on the floor of the New York Stock Exchange March 5, 2015. REUTERS/Brendan McDermid/File Photo (Reuters) - AbbVie Inc said on Tuesday that the ...